RAC1 is a small GTPase that functions as a molecular switch regulating actin cytoskeleton dynamics and cell motility. As a GTP-binding protein, RAC1 cycles between inactive GDP-bound and active GTP-bound states, with its activity modulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins 1. RAC1 controls lamellipodium assembly and focal adhesion dynamics, enabling cell migration and invasion 2. In epithelial tissues, RAC1 regulates cytoskeletal rearrangement critical for physiological cell shedding and barrier integrity; impaired RAC1 function causes cell overcrowding, tight junction redistribution, and epithelial leakage 3. RAC1 mediates exercise-induced muscle protein synthesis and glycogen resynthesis through p38MAPK signaling and NOX2-dependent mechanisms 4. RAC1 promotes smooth muscle contraction and proliferation via actin polymerization 5. Disease relevance is substantial: RAC1(P29S) is the third most common melanoma mutation (4-7% of patients), remaining constitutively GTP-bound and promoting proliferation and migration 6. RAC1 hyperactivation drives prostate cancer progression through VAV2-mediated EGFR signaling, with VAV2 overexpression correlating with poor prognosis 7. RAC1 silencing inhibits epithelial-mesenchymal transition and metastatic potential in gastric cancer 8. Mutations cause intellectual developmental disorder, autosomal dominant 48. RAC1 represents a therapeutic target across multiple cancers and inflammatory conditions.